Are Analysts Bearish Neos Therapeutics, Inc. (NASDAQ:NEOS) After Last Week?

June 17, 2018 - By Henry Gaston

Neos Therapeutics, Inc. (NASDAQ:NEOS) Logo

Neos Therapeutics, Inc. (NASDAQ:NEOS) Ratings Coverage

Among 2 analysts covering Neos Therapeutics (NASDAQ:NEOS), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Neos Therapeutics had 2 analyst reports since January 31, 2018 according to SRatingsIntel. The stock of Neos Therapeutics, Inc. (NASDAQ:NEOS) has “Market Perform” rating given on Wednesday, January 31 by BMO Capital Markets. The stock of Neos Therapeutics, Inc. (NASDAQ:NEOS) earned “Buy” rating by Cantor Fitzgerald on Thursday, March 15. Below is a list of Neos Therapeutics, Inc. (NASDAQ:NEOS) latest ratings and price target changes.

15/03/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $20.0 Maintain
31/01/2018 Broker: BMO Capital Markets Old Rating: Outperform New Rating: Market Perform Downgrade

The stock decreased 1.47% or $0.1 during the last trading session, reaching $6.7. About 222,471 shares traded. Neos Therapeutics, Inc. (NASDAQ:NEOS) has declined 16.87% since June 17, 2017 and is downtrending. It has underperformed by 29.44% the S&P500.

Neos Therapeutics, Inc., a pharmaceutical company, engages in the development, manufacture, and commercialization of products for the treatment of attention deficit hyperactivity disorder using its drug delivery technologies. The company has market cap of $194.28 million. The Company’s product candidates are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms. It currently has negative earnings. The firm makes and markets generic Tussionex, a hydrocodone polistirex and chlorpheniramine polistirex XR liquid suspension product indicated for the relief of cough and upper respiratory symptoms associated with allergies or colds in adults and children of six years of age and older.

More news for Neos Therapeutics, Inc. (NASDAQ:NEOS) were recently published by: Globenewswire.com, which released: “Neos Therapeutics to Participate in Two June Conferences” on May 31, 2018. Livetradingnews.com‘s article titled: “Neos Therapeutics, Inc. (NASDAQ:NEOS) Value Stock at $6.50” and published on June 11, 2018 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.